Comprehensive Management of Chronic Kidney Disease (CKD)

Core Management Strategies

The American College of Cardiology recommends moderate-intensity physical activity for at least 150 minutes per week, adjusted to the patient's cardiovascular and physical tolerance 3
The Kidney Disease: Improving Global Outcomes (KDIGO) guidelines advise patients to avoid sedentary behavior and provide specific guidance on exercise intensity based on fall risk 3
The National Kidney Foundation suggests encouraging smoking cessation as tobacco use accelerates CKD progression 4
The Academy of Nutrition and Dietetics recommends targeting optimal body weight with weight loss recommendations for patients with obesity 3
The American Heart Association recommends healthy, diverse diets with higher consumption of plant-based foods compared to animal-based foods and lower consumption of ultraprocessed foods 3
The National Institute of Diabetes and Digestive and Kidney Diseases suggests maintaining protein intake at 0.8 g/kg body weight/day for adults with CKD G3-G5 and avoiding high protein intake (>1.3 g/kg/day) in those at risk of progression 3
The American College of Cardiology recommends reducing sodium intake to <2 g per day to help control blood pressure and reduce proteinuria 4

The American College of Cardiology recommends targeting blood pressure ≤130/80 mmHg for patients with albuminuria ≥30 mg/24 hours 5
The American Heart Association suggests targeting blood pressure ≤140/90 mmHg for patients with urine albumin excretion <30 mg/24 hours 5
The Kidney Disease: Improving Global Outcomes (KDIGO) guidelines recommend using angiotensin-converting enzyme inhibitors (ACEIs) or angiotensin receptor blockers (ARBs) as first-line therapy for patients with albuminuria >300 mg/24 hours 5, 4
The American College of Cardiology suggests adding dihydropyridine calcium channel blockers and/or diuretics as needed to achieve blood pressure targets 3, 6

The Kidney Disease: Improving Global Outcomes (KDIGO) guidelines recommend implementing comprehensive diabetes management according to KDIGO guidelines 1
The American Diabetes Association suggests using metformin as first-line therapy when eGFR ≥30 ml/min/1.73m² 1, 7
The European Association for the Study of Diabetes recommends adding SGLT2 inhibitors when eGFR ≥20 ml/min/1.73m² and continuing until dialysis or transplantation 1, 7
The American Diabetes Association suggests considering GLP-1 receptor agonists when SGLT2 inhibitors and metformin are insufficient to meet glycemic targets 1, 7
The American College of Physicians recommends targeting hemoglobin A1c level of approximately 7% 4

The American College of Cardiology recommends prescribing statins for all adults aged ≥50 years with CKD (regardless of GFR category) 2, 8
The American Heart Association suggests recommending statin therapy for adults aged 18-49 years with CKD if they have coronary disease, diabetes, prior stroke, or 10-year coronary event risk >10% 2, 8
The European Atherosclerosis Society recommends adding ezetimibe based on ASCVD risk and lipid levels 3, 6
The American College of Cardiology suggests considering antiplatelet therapy for patients with established cardiovascular disease 1, 6

The Kidney Disease: Improving Global Outcomes (KDIGO) guidelines recommend considering pharmacological treatment with or without dietary intervention when serum bicarbonate <18 mmol/l 2
The National Kidney Foundation suggests monitoring treatment to ensure bicarbonate doesn't exceed the upper limit of normal or adversely affect blood pressure, potassium, or fluid status 2
The American College of Physicians recommends implementing an individualized approach for patients with CKD G3-G5 and hyperkalemia, including dietary and pharmacologic interventions 2
The European Renal Association suggests limiting intake of foods rich in bioavailable potassium (e.g., processed foods) for patients with history of hyperkalemia 2
The Kidney Disease: Improving Global Outcomes (KDIGO) guidelines recommend being aware of factors affecting potassium measurement including diurnal variation, sample type, and medication effects 2

The American College of Physicians recommends assessing risk factors regularly (every 3-6 months) 1, 7
The National Kidney Foundation suggests monitoring for CKD progression using both blood and urine tests, with frequency guided by individual risk 6
The Kidney Disease: Improving Global Outcomes (KDIGO) guidelines recommend considering all people with CKD at increased risk for acute kidney injury (AKI) 5, 4
The American College of Cardiology suggests using validated risk equations to estimate absolute risk of kidney failure for individual patients 6
The National Institute of Diabetes and Digestive and Kidney Diseases recommends recognizing that small fluctuations in GFR are common and do not necessarily indicate progression 4

The European Renal Association recommends regularly screening for symptoms using validated tools 9
The American College of Physicians suggests addressing pain using a stepwise approach, starting with non-pharmacological interventions and advancing to pharmacological therapy as needed 9
The Kidney Disease: Improving Global Outcomes (KDIGO) guidelines recommend screening for and treating depression, which affects approximately 26.5% of patients with CKD stages 1-4 9

The Academy of Nutrition and Dietetics recommends referring patients to renal dietitians or accredited nutrition providers for dietary education tailored to individual needs 3
The American College of Physicians suggests considering referral to other specialists (psychologists, pharmacists, physical therapy) as indicated 3

The American Geriatrics Society recommends providing specific advice on exercise intensity and type for patients at higher risk of falls 3
The World Health Organization suggests adapting recommendations for physical activity considering age, ethnic background, comorbidities, and resource access 3
The American Academy of Pediatrics recommends encouraging physical activity aiming for 60 minutes daily and achievement of healthy weight for children with CKD 3